Treatment Trials

Below is a listing by cancer type of the current treatment clinical trials for cancer offered through the Genesis Cancer Care Institute and Iowa Cancer Specialists. See clinical trials offered by Hematology-Oncology Associates of the Quad-Cities, PC

Each trial below is linked to a complete description provided by the National Cancer Institute. You may then choose a patient version or health professional version to read and print out as you wish. If you need assistance with this process, contact us. You may search for other clinical trials through the following links: National Cancer Institute Clinical Trial Search; Emerging Med; Trial Check; or Center Watch.

 Breast Cancer Leukemia
 Carcinoid Tumor Lung (Non-Small Cell)
 Gastro-Intestinal Lung (Small Cell)
 Genito-Urinary (Prostate; Kidney) Lymphoma 
 Gynecology (Endometrial; Ovarian Epithelial) Melanoma 
 Head & Neck Miscellaneous
  Multiple Myeloma

Breast Cancer

ECOG-ACRIN E2112Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer

NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel + Cyclophosphamide or Four Cycles of Doxorubicin + Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy + Trastuzumab in Women With Node-Positive or High Risk Node-Negative HER2-Low Invasive Breast Cancer

SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer (RS) of 25 or Less – Step 1 with Recurrence Score

SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of EVEROLIMUS in Patients with High-Risk, Homone Receptor-Positive AND HER2/neu Negative Breast Cancer

back to top

Carcinoid Tumor

back to top

Gastro-Intestinal (Colon Cancer; Rectal Cancer; Gastrointestional Stromal Tumor)

CALGB/SWOG 80702: Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer

SWOG S1201: A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastroesophageal Junction (GEJ) Cancer

ECOG-ACRIN E7208: A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab, in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy

back to top

Genito-Urinary (Prostate; Kidney)

CALGB 90203: Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy vs Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer

SWOG S0931: EVEREST--EVErolimus for Renal Cancer Ensuing Surgical Therapy, a Phase III Study

A031201:  Phase III Trial of Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer

SWOG S1216Phase III Randomized TRial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

back to top

GYNECOLOGY (Endometrial; Ovarian Epithelial)

back to top

Head & Neck

back to top

Leukemia (Acute Myeloid (AML) Adult; Chronic Lymphocytic (CLL))

back to top

Lung (Non-Small Cell)

ECOG-ACRIN  E5508: Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Lung (Small Cell)

ECOG-ACRIN E2511:  Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer

back to top

Lymphoma

back to top

Melanoma

back to top

Miscellaneous

back to top

Multiple Myeloma

ECOG-ACRIN E3A06: Randomized Phase III Trial of Lenalidomide vs Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma 

ECOG-ACRIN E1A11Randomized Phase III Trial of Bortezomib. LENalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myelome (ENDURANCE)

back to top

Contact Us

For more information about our cancer services, please contact:

563-421-1909
800-446-6088
Email

Cancer Nurse Navigators

Cancer Nurse Navigators

You've been told you have cancer. Let our Cancer Nurse Navigators guide the way. Call Genesis Cancer Care Institute today.

563-421-1029
563-421-1030


Read more about our Cancer Nurse Navigators.

Dietitian's Blog

Teresa Pangan

Teresa Pangan, Cancer Care Dietitian, can help you incorporate healthy eating habits into your cancer care plan. 

Read Teresa's most recent post here.

© 2014 Genesis Health System - All rights reserved.

1227 E. Rusholme Street Davenport, IA 52803 563-421-1000